$0.3550
0.01394.08%
Last update: Nov 12, 4:07 PM
Oragenics Inc
OGENAMEX
Oragenics fell 70.6% from $1.16 to $0.34, behind the S&P 500's +11.2%. Its worst day was Feb 5 (−13.5%), and its low came Nov 11 at $0.34.
Nov 12, 2025 – Nov 11, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
Oragenics shares fell 13.5%, while the S&P 500 fell 1.2%.
−13.5%, the year's worst day · S&P 500 −1.2%
Oragenics shares rose 12.5%, while the S&P 500 rose 0.5%.
+12.5% · S&P 500 +0.5%
Story events cover the past 12 months · Times ET
Oragenics shares rose 11.1%, while the S&P 500 fell 0.6%.
+11.1% · S&P 500 −0.6%
EPS of $0.60 was reported on $0.00 revenue.
−3.0% · S&P 500 +0.3%
Oragenics shares rose 11.2%, while the S&P 500 rose 2.9%.
+11.2% · S&P 500 +2.9%
Mackay Base Hospital activated March 31, 2026 as first clinical trial site; first patient dosed within days of activation — a signal of strong enrollment velocity and significant unmet medical need
+13.0%, the year's best day · S&P 500 +1.0%
EPS of $-0.51 was reported on $0.00 revenue.
−6.6% · S&P 500 +0.2%
EPS of $-0.57 was reported on $0.00 revenue.
+0.5% · S&P 500 −0.2%
Where it ended: a close of $0.34 on Nov 11, 2026. Up next: Q3 2026 earnings on Nov 24, 2026.
Nothing in the past 12 months.
All OGEN analyst actionsNothing in the past 12 months.
All OGEN dividend historyChart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for OGEN and SPY from Benzinga historical bars. Not investment advice.
